PubRank

Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 27867062)

Published in J Infect on November 17, 2016

Authors

F Sahr1, R Ansumana2, T A Massaquoi3, B R Idriss1, F R Sesay3, J M Lamin4, S Baker5, S Nicol6, B Conton7, W Johnson8, O T Abiri8, O Kargbo5, P Kamara5, A Goba9, J B W Russell8, S M Gevao8

Author Affiliations

1: 34 Military Hospital, Wilberforce, Freetown, Sierra Leone; College of Medicine and Allied Health Sciences, Freetown, Sierra Leone.
2: Mercy Hospital Research Laboratory, Kulanda Town, Bo, Sierra Leone; Njala University, Bo, Sierra Leone. Electronic address: rashidansumana@gmail.com.
3: 34 Military Hospital, Wilberforce, Freetown, Sierra Leone.
4: Mercy Hospital Research Laboratory, Kulanda Town, Bo, Sierra Leone; Njala University, Bo, Sierra Leone.
5: Ministry of Health and Sanitation, Sierra Leone.
6: Davidson Nicol Memorial Hospital, Freetown, Sierra Leone.
7: Physio - Fitness and Rehabilitation Centre, Freetown, Sierra Leone.
8: College of Medicine and Allied Health Sciences, Freetown, Sierra Leone; Ministry of Health and Sanitation, Sierra Leone.
9: Lassa Fever Laboratory, Kenema Government Hospital, Sierra Leone.

Associated clinical trials:

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection | NCT04343755

Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure | NCT04353206

Convalescent Plasma Trial in COVID -19 Patients | NCT04356534

Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia (COP-COVID-19) | NCT04358783

Passive Immunity Trial of Nashville II for COVID-19 (PassItOnII) | NCT04362176

Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia | NCT04374565

Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD | NCT04411602

Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients | NCT04420988

Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection | NCT04456413

Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19 | NCT04467151

Articles citing this ↘

Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review. Curr Ther Res Clin Exp (2017) 0.75